hotspot -WSS

hotspot

author：explore 2025-09-30 17:32:07 - browse：6

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Cue Health's Covid

entertainment

WSS

Hospitals need to get ahead of regulations on climate change

Decentralized clinical trials need collaboration to achieve wider use

Cell therapy fails to slow type 1 diabetes, but safety is established

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Dogs on Prozac: What pet anti

focus

hotspot

Wikipedia

In Memoriam: Notable people who died in 2023

J&J reports mixed data on next

Psychedelics group wrestles with new pharma identity

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Walensky prepares to leave CDC — and Congress — behind

Q&A: Jennifer Adair on making gene therapy available globally

Continuity nursing helped my family in our darkest PICU moments

UnitedHealth financials solid despite Change Healthcare cyberattack

focus

The Bio Revolution is changing business and society

Key Senate committee drafts bipartisan bill to stem drug shortages

Unmasking the 'centricity' illusion in clinical trials

Lawsuit challenges CMS nursing home minimum staffing rule

MassMutual is introducing free genetic testing for members

Bird flu makes raw milk dangerous to consume, mouse study finds

entertainment

focus

focus

knowledge